title: Clinical management of vitreomacular traction.
abstract: OBJECTIVE
  To describe recent evidence regarding the clinical management of vitreomacular traction (VMT).
  
  
  RESULTS
  Recent studies have reported favorable outcomes in patients with VMT managed with observation, pharmacologic vitreolysis with ocriplasmin, and intravitreal perfluoropropane gas. Subgroup analysis has identified features associated with spontaneous release of VMT as well as features associated with successful pharmacologic release of VMT with ocriplasmin.
  
  
  CONCLUSIONS
  Observation may be an appropriate initial recommendation for patients with mild VMT. When treatment is necessary, pharmacologic vitreolysis with ocriplasmin is an effective nonsurgical therapeutic option. Careful patient selection improves success rates with ocriplasmin. Further study is necessary to establish the efficacy of intravitreal perfluoropropane gas for VMT as well as the efficacy of ocriplasmin in patients with VMT and concurrent retinal disease. As these treatments are more widely used, prospective data will continue to clarify their risk/benefit profile.
authors.affiliation: Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Mohammed Ali
authors.initials: MA
authors.lastname: Khan
authors.forename: Julia A
authors.initials: JA
authors.lastname: Haller
mesh_terms: D058450:Endotamponade; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005466:Fluorocarbons / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D010446:Peptide Fragments / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000628:therapy*; D018570:Risk Assessment; D000267:Tissue Adhesions; D020255:Vitreous Detachment / Q000628:therapy*
chemical_list: D005343:Fibrinolytic Agents; D005466:Fluorocarbons; D010446:Peptide Fragments; C054561:microplasmin; C042852:perflutren; D005341:Fibrinolysin